DOJ Battles Over Trans Patient Data & Health Data as Utility? – STAT News Roundup

Good morning. A flurry of developments this week touches on trust in public health figures, the ongoing legal battles surrounding gender-affirming care, and lingering questions about common medications. Plus, a new look at how medical schools are approaching nutrition education.

The Erosion of Trust and the Persistence of Misinformation

Recent polling data from the Annenberg Public Policy Center at the University of Pennsylvania reveals a notable divide in public trust, with Americans generally exhibiting more confidence in career scientists at federal health agencies than in the political appointees who lead them. The survey, conducted in February among 1,650 U.S. Adults, found that two-thirds of respondents expressed confidence in career scientists, compared to just 43% for agency leaders. This disparity underscores a growing skepticism towards politicization within public health.

Notably, Anthony Fauci, the former director of the National Institute of Allergy and Infectious Diseases, garnered more favorable ratings than both current Health and Human Services Secretary Robert F. Kennedy Jr. And Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services. This finding is particularly striking given the ongoing debates surrounding the COVID-19 pandemic and the spread of misinformation. The data suggests a continued reliance on established scientific expertise, even amidst broader distrust in institutions.

Legal Battles Intensify Over Gender-Affirming Care

The legal landscape surrounding gender-affirming care continues to shift, with oral arguments beginning today in a Ninth Circuit court case that could determine the extent to which the Justice Department can access patient records from telehealth company QueerDoc. The DOJ is seeking access to sensitive information – including names, Social Security numbers, and diagnoses – as part of a broader investigation into the provision of gender-affirming care to young people. STAT’s Theresa Gaffney provides in-depth coverage of the case, its potential outcomes, and the wider implications for access to care.

This case stems from a suite of 20 subpoenas issued by the DOJ to clinics and doctors providing medication or surgery to transgender youth. A district judge initially halted the subpoena issued to QueerDoc in October, a decision the federal government is now appealing. The outcome of this first case is expected to influence the DOJ’s strategy in other pending appeals, which are likely to extend through the finish of the year. The Trump administration’s efforts to restrict pediatric gender-affirming treatment have already led many hospitals to pause or discontinue these services, raising concerns about equitable access to healthcare.

Rethinking Patient Health Data: A Public Utility Model?

A provocative idea is gaining traction within public health circles: treating patient health data as a public utility. Last year, the Department of Health and Human Services proposed a framework that would view patient data as a valuable commodity, akin to electricity, fostering innovation and progress. This concept was further explored in a recent piece published in Science, where researchers and companies argued that individuals should have greater control over their health data, understanding how it’s used and mediating access.

The core argument is that if health data is recognized as a valuable resource, it should be governed and protected like a public utility, preventing exploitation and ensuring responsible use. STAT’s Katie Palmer spoke with Alastair Thomson, former chief data officer of ARPA-H, about the origins of this idea and its feasibility. Read more about this evolving discussion and its potential impact on the future of healthcare.

The Unintended Consequences of Misinformation: Tylenol and Autism

A new study published yesterday highlights the potentially harmful consequences of spreading misinformation about medication safety. Researchers found that acetaminophen (Tylenol) use in emergency departments for pregnant women plummeted following a press conference last year in which President Trump and his health officials cautioned against its use, citing a purported link to autism. The study revealed that orders for acetaminophen decreased significantly in the twelve weeks after the announcement, while prescriptions for leucovorin – a cancer drug with limited evidence of effectiveness in alleviating autism symptoms – dramatically increased.

This shift in prescribing patterns occurred despite the scientific consensus finding no causal link between acetaminophen use and autism, and despite the known risks associated with untreated fevers during pregnancy. The findings underscore the importance of relying on evidence-based information and the potential dangers of disseminating unsubstantiated claims. It’s a stark reminder of how political rhetoric can influence medical decision-making and potentially harm patient health.

Semaglutide Pills and the Future of Obesity Care

The growing availability of semaglutide in pill form – alongside the established injectable versions like Ozempic – is poised to further transform obesity care. Alex Hogan’s latest STATus Report video explores the potential impact of these new medications, and delves into the question of whether Novo Nordisk is intentionally targeting Hims & Hers with their latest advertising campaign. Watch the video to learn more about the evolving landscape of weight loss treatments.

Medical School Curricula to Prioritize Nutrition Education

In a surprising turn, more than 50 medical schools have agreed to revamp their nutrition education programs at the behest of the Trump administration. The agreements, unveiled Thursday, demonstrate a willingness to find common ground even amidst ongoing disagreements over issues like vaccine policy. The schools will conduct curriculum assessments, nominate faculty champions, and publicly outline plans to incorporate at least 40 hours of nutrition education – or its equivalent – starting in the fall of 2026. Read more from STAT’s Sarah Todd about this unexpected development.

Looking Ahead: The coming months will be critical for several of these storylines. The Ninth Circuit’s decision on the QueerDoc subpoena will set a precedent for the DOJ’s broader strategy regarding gender-affirming care. Further research and debate are needed to refine the concept of patient health data as a public utility, balancing innovation with privacy concerns. And ongoing efforts to combat misinformation will be essential to ensure that public health decisions are based on sound scientific evidence.